Absence of a pharmacokinetic interaction between entecavir and adefovir

Journal of Clinical Pharmacology

Volumn 47, Issue 10, 2007, Pages 1327-1334

  Bifano, Marc ^a,c   Yan, Jing He ^b   Smith, Robert A ^a   Zhang, Duxi ^a   Grasela, Dennis M ^a   LaCreta, Frank ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Adefovir; Drug interactions; Entecavir; Hepatitis B virus; Pharmacokinetics

Indexed keywords

ADEFOVIR; ENTECAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG FATALITY; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; PHARMACOKINETICS;

ADENINE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; GUANINE; HUMANS; MALE; PHOSPHONIC ACIDS;

EID: 34648813243     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007304780     Document Type: Article

References (18)

1. Innaimo SF, Seifer M., Bisacchi GS, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997 ; 41: 1444-1448.
2. Colonno RJ, Genovesi EV, Medina I., et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis. 2001 ; 184: 1236-1245.
3. Lai CL, Leung N., Teo EK, et al. Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005 ; 129: 528-536.
4. Peters MG, Hann HW, Martin P., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine resistant chronic hepatitis B. Gastroenterology. 2004 ; 126: 91-101.
5. Delaney WE, Yang H., Miller MD, Gibbs C., Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother. 2004 ; 48: 3702-3710.
6. Korba BE, Cote P., Hornbuckle W., et al. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks. Antivir Ther. 2000 ; 5: 95-104.
7. Thorn JA, Jarvis SM Adenosine transporters. Gen Pharmacol. 1996 ; 27: 613-620.
8. Wang J., Schaner ME, Thomassen S., et al. Functional and molecular characteristics of Na+-dependent nucleoside transporters. Pharm Res. 1997 ; 14: 1524-1531.
9. Cass CE, Young JD, Baldwin SA, et al. Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Biochem Cell Biol. 1998 ; 76: 761-770.
10. Nelson JA, Vidale E., Enigbokan M., et al. Renal transepithelial transport of nucleosides. Drug Metab Dispos. 1988 ; 16: 789-792.
11. Mangravite LM, Lipschutz JH, Mostov KE, et al. Localization of GFP-tagged concentrative nucleoside transporters in a renal polarized epithelial cell line. Am J Physiol Renal Physiol. 2001 ; 280: F879 - F885.
12. Gibaldi M. Non-compartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D, eds. Pharmacokinetics. 2 nd ed. New York, NY: Marcel Dekker ; 1982: 409-418.
13. Riegelman S. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm. 1980 ; 8: 509-534.
14. Ronaldson PT, Bendayan R. Renal drug transport and drug-drug interactions. J Clin Pharm Pract. 2002 ; 15.6: 490-503.
15. Mulato AS, Ho ES, Cihlar T., et al. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir medicated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 ; 295: 10-15.
16. Gihlar T., Lin DC, Pritchard JB, et al. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol. 1999 ; 56: 570-580.
17. Colonno R., Discotto L., Gong Y-F., Kimmel B., Weinheimer S. Combination studies involving entecavir and HIV nucleoside reverse transcriptase inhibitors showed no antagonistic effects on HBV or HIV activity in vitro. Paper presented at: 39th Annual Meeting of the European Association for the Study of the Liver; April 14-18 2004 ; Berlin, Germany.
18. Wolf DL, Rodriguez CA, Mucci M., Ingrosso A., Duncan BA, Nickens DJ Pharmacokinetics and renal effects with a reduced dose of probenicid in HIV-infected patients with cytomegalovirus retinitis. J Clin Pharmacol. 2003 ; 43: 43-51.